Compositions for stimulation of mammalian innate immune resistance to pathogens

Patent metadata

Field	Value
Publication number	US-12201684-B2
Application number	US-202016937967-A
Country	US
Kind code	B2
Filing date	Jul 24, 2020
Priority date	Mar 25, 2009
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.

First claim

The invention claimed is:

1. A method of treating, inhibiting, or attenuating a viral infection comprising administering a composition comprising PAM2CSK4 and a type C CpG oligodeoxynucleotide (ODN) to an individual that has or is at risk of viral infection; wherein 5-100 μg of PAM2CSK4 and 10-150 μg of type C CpG ODN is administered.

2. The method of claim 1 , wherein the virus is a Adenoviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Herpesviridae, Orthomyxoviridae, Paramyxovirinae, Pneumovirinae, Picomaviridae, Poxyiridae, Retroviridae, or Togaviridae.

3. The method of claim 1 , wherein the virus is Influenza, H5N1, Marburg, Ebola, Severe acute respiratory syndrome coronavirus (SARS-COV), yellow fever virus, human respiratory syncytial, or Vaccinia virus.

4. The method of claim 1 , wherein the composition is administered by nebulization.

5. A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of a composition comprising an aerosolized PAM2CSK4 and a type C CpG ODN in combination with an orally administered composition comprising an anti-viral pharmaceutical to an individual that has or is at risk of viral infection; wherein 5-100 μg of PAM2CSK4 and 10-150 μg of type C CpG ODN is administered.

6. The method of claim 5 , wherein the ODN is ODN2395 or ODNM362 or ODN10101.

7. The method of claim 5 , wherein the antiviral pharmaceutical is oseltamivir or ribavirin.

8. The method of claim 5 , wherein the antiviral pharmaceutical is a neuraminidase inhibitor.

9. The method of claim 1 , wherein the composition further comprises an antiviral pharmaceutical that inhibits viral replication or synthesis, or inhibits viral protease activity.

10. The method of claim 1 , wherein the ODN comprises ODNM362.

11. The method of claim 1 , wherein the type C CpG ODN is ODN2395 or ODNM362 or ODN10101.

12. The method of claim 1 , wherein the composition is formulated for administration to the lungs.

13. The method of claim 1 , wherein the individual is one that is being treated with an anti-viral pharmaceutical.

14. The method of claim 13 , wherein the antiviral pharmaceutical is oseltamivir or ribavirin.

15. The method of claim 13 , wherein the antiviral pharmaceutical is a neuraminidase inhibitor.

16. A method of treating, inhibiting, or attenuating a viral infection comprising administering a composition comprising PAM2CSK4 and ODNM362 to an individual that has or is at risk of viral infection; wherein 5-100 μg of PAM2CSK4 and 10-150 μg of type C CpG ODN is administered by nebulization to the individual.

Assignees

• Univ Texas

Inventors

• Dickey Burton
• Tuvim Michael
• Evans Scott

Classifications

• A61K2039/55516

  Proteins; Peptides · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/7125

  Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters · CPC title